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Abstract 
Epigenetics has become a promising field for finding new biomarkers and improving diagnosis, prognosis, and drug 
response in inflammatory bowel disease. The number of people suffering from inflammatory bowel diseases, espe-
cially Crohn’s disease, has increased remarkably. Crohn’s disease is assumed to be the result of a complex interplay 
between genetic susceptibility, environmental factors, and altered intestinal microbiota, leading to dysregulation of 
the innate and adaptive immune response. While many genetic variants have been identified to be associated with 
Crohn’s disease, less is known about the influence of epigenetics in the pathogenesis of this disease. In this review, 
we provide an overview of current epigenetic studies in Crohn’s disease. In particular, we enable a deeper insight into 
applied bioanalytical and computational tools, as well as a comprehensive update toward the cell-specific evaluation 
of DNA methylation and histone modifications.
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Background
Crohn’s disease (CD) belongs to the group of inflam-
matory bowel diseases (IBD) and is a relapsing systemic 
chronic inflammatory disease that affects the gastroin-
testinal tract with extra-intestinal manifestations and 
associated immune disorders. Although various therapies 
have been developed (e.g., immunosuppressants, immu-
nomodulators, biologicals), there is still no cure for CD 
[1]. It is known that genetic susceptibility is a significant 
risk factor for the disease. However, environmental fac-
tors, such as diet [2], smoking [3], early antibiotic treat-
ment [4], and the intestinal microbiome [5], also play a 
critical role in the pathogenesis [6]. The importance 
of lifestyle is supported by the rising incidence of CD 
in newly industrialized countries in Africa, Asia, and 
South America [7]. Epigenetic modifications influenced 
by environmental factors might help to understand the 
increasing CD incidence [8, 9]. Recently, the analysis of 
epigenetic changes like DNA methylation or histone 
modification is recognized as highly useful to identify 
new biomarkers or targets for drug therapy, which is 
essential to apply a more targeted treatment in CD [1]. 
For example, epigenetic alterations in colorectal cancer, 
allergy and asthma, and cardiovascular disease serve 
as clinical biomarkers for diagnostic, prognostic, and 
therapeutic purposes [10–12]. Based on these findings, 
alterations in DNA methylation between CD patients 
and healthy controls may likewise be used to identify bio-
markers and to improve IBD management.
Principles of epigenetics
Epigenetics is defined as a change in the organism’s phe-
notype that persists through mitosis and even meio-
sis without altering the underlying DNA sequence [13]. 
Consequently, epigenetics is generally understood to be 
the study of mechanisms that control gene expression 
in response to environmental influences in a potentially 
inheritable manner [14]. Complex epigenetic states can 
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be induced by several converging and amplifying sig-
nals, including transcription factors, non-coding RNAs, 
DNA-methylation, and histone modifications. All of 
these processes are dynamic and reversible. Epigenetic 
changes are involved in the correct development of cells 
and their functions, cell differentiation, and homeostasis 
but are also associated with numerous diseases [13]. Sev-
eral comprehensive reviews that explained in detail the 
molecular epigenetic mechanisms have been published 
on the potential value of epigenetics in IBD during recent 
years to which we refer the reader [13, 15–17]. In this 
review, we provide a deeper insight into applied bioana-
lytical and computational tools for epigenetic analysis, 
as well as a comprehensive update on CD-specific epi-
genetic alterations using DNA methylation and histone 
modifications for biomarker discovery.
DNA methylation
The most widely studied epigenetic modification in 
mammals is DNA methylation, which occurs through 
the covalent bonding of a methyl group to the 5′ carbon 
of the cytosine residue. When methylation occurs near a 
promoter sequence, gene expression is inactivated, either 
because proteins bind to the methylated CpG island and 
initiate DNA compensation and inactivation or meth-
ylation itself blocks the DNA sequence and transcription 
factors are unable to bind. The conversion of cytosine to 
5-methylcytosine is catalyzed by special enzymes called 
DNA methyltransferases (DNMTs) [18]. In contrast, 
5-methylcytosines are converted back to unmethylated 
cytosines by ten-eleven translocation (TET) proteins with 
the help of a metabolite intermediate, α-ketoglutarate 
(α-KG), and molecular oxygen as enzyme cofactors for 
this reaction [19, 20].
Histone modification
The DNA themselves is packed together with histones 
to form chromatin, whereby 147 bp of DNA is wrapped 
1.7 times around a core of 8 histone proteins [21, 22]. The 
N- and C-terminal tails of the nuclear histones stick out 
from the nucleosome and are responsible for mediating 
the folding of the chromatin [21]. Various amino acids 
on the histone tails, namely lysine, arginine, serine, and 
threonine, are epigenetically altered by enzymes, which 
then influences if a gene is accessible for binding by tran-
scription factors and the RNA polymerase II machin-
ery. In compact form, named heterochromatin, DNA 
is less accessible to these factors, so gene expression is 
suppressed [21]. Conversely, relaxed so-called euchro-
matin is more accessible, and genes can be transcribed 
[21, 23]. There are several different classes of histone-
modifying enzymes; these modifications include acetyla-
tion and deacetylation, methylation and demethylation, 
phosphorylation, ubiquitination, sumoylation, crotonyla-
tion, ADP-ribosylation, and deamination [16, 24].
Tools for biostatistics
Epigenetics data analysis and integration of further 
experimental datasets
The variety of technologies to investigate epigenetic 
modifications has also led to a broad landscape of data 
analysis tools, in which the bottleneck has shifted from 
data generation toward their analysis, posing new chal-
lenges for the interpretation of results.
Each of the different platforms to investigate DNA-
methylation and histone modification commonly include 
chip-based arrays, chromatin immunoprecipitation fol-
lowed by DNA-sequencing (ChIP-Seq), assay for trans-
posase accessible chromatin with high-throughput 
sequencing (ATAC-Seq), or single-cell technologies that 
each have its own specific set of analysis tools. In gen-
eral, all analyses contain data processing steps of quality 
control, batch correction, bias detection, genetic varia-
tion detection (i.e., sequence analysis, peak calling), and 
differential methylation detection. The Encyclopedia of 
DNA Elements (ENCODE) consortium performs data 
curation and also offers standardized processing pipe-
lines for various assay types online (https:// www. encod 
eproj ect. org/), with regular updates [28]. Specific pitfalls, 
e.g., during sequence analysis, peak calling, or differen-
tial methylation detection, can be obtained in dedicated 
review articles [29–32]. Novel analysis methods can also 
be utilized entirely online on dedicated data processing 
servers, such as Galaxy [33]. A summary of computa-
tional protocols used for epigenetic studies in CD is pre-
sented in Tables 1 and 2.
Similar to transcriptomics, epigenetic profiles are 
continuous, dynamic, and tissue-specific, so the chal-
lenges are also more and more focused on data analysis 
approaches to facilitate the identification of coordinated 
epigenetic changes and interpretation of their func-
tional consequences in normal development and disease 
[34]. Therefore, integration of multiple omics datasets 
might enable an in-depth understanding of the inter-
play between various cogs of the transcriptional machin-
ery [35], especially an essential asset to investigate CD. 
For example, the ENCODE database [36] incorporates 
numerous CD-related datasets on gene expression, 
ChIP-Seq (transcription factor binding, histone modi-
fications), genome-wide association studies (GWAS), 
and expression quantitative trait loci (eQTL) obtained 
from multiple cell types. Successfully applied epigenet-
ics integration studies that utilized RNA-Seq and ChIP-
Seq or single-cell RNA-Seq and single-cell ChIP-Seq have 
already been reported for other diseases [37–39]. The 
extended use of single-cell RNA-Seq data continues with 
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novel approaches that apply cell type deconvolution to 
infer bulk tissue DNA methylomes [40]. Interestingly, the 
epigenetic clock developed by Horvath [41] utilizes DNA 
methylation data only to provide an estimate of age; how-
ever, the testing data used in generating this clock did not 
have a large representation of tissue from elderly individ-
uals, and as such, it is unclear if the clock is accurate in 
older age groups or those with age-related diseases [42]. 
These novel experimental and computational methods 
can be essential to investigate currently limited cell type-
dependent influences, e.g., monocytes, macrophages, in 
CD patients.
Application of machine learning algorithms to decipher 
important epigenetic modifications used for patient 
classification
Despite the fact that novel experimental and computa-
tional technologies have become available, the applica-
tion to specific CD examples is limited.
Machine learning (ML) and deep learning (DL) are 
subsets of currently widely used artificial intelligence 
technologies, in which computer algorithms are used to 
autonomously learn from given data and information. 
Current reviews of Hamamoto et al. [43] and Rauschert 
et al. [44] also foresee integrated epigenetics analyses of 
“medical big data” or omics data as essential, and both 
show the general advantages and pitfalls of ML and DL 
technologies. In total, sixteen studies were identified 
that utilize ML and epigenetics data to diagnose or clas-
sify diseases [44]. Exemplarily for clinical epigenetics in a 
routine diagnostic setting, Capper et al. already demon-
strated the applicability of an ML-based approach for the 
classification of central nervous system tumors by using 
DNA-methylation data [45]. This study suggests that 
such a predictive DNA methylation-based classification 
model might substantially influence diagnostic preci-
sion compared to current standard methods, resulting in 
a change of diagnosis in up to 12% of prospective cases. 
Taking into account the growing number of reported 
epigenetic alterations in diseases, this offers a chance to 
increase sensitivity and specificity of future diagnostics 
and therapies in general [44].
Network modeling and functional analyses for epigenetics 
data integration
Network-based modeling approaches already present 
valuable insights to understand and improve the percep-
tion of complex disease states and their initial causes. To 
date, network analysis provides reliable and cost-effective 
approaches for early disease detection, prediction of co-
occurring diseases and interactions, and drug design [46]. 
For example, gene promoter annotation combined with 
network analysis and sequence-resolution of enriched 
transcriptional motifs in epigenetics data can reveal 
transcription factor families that act synergistically with 
epigenetic master regulators [47]. Wilson et al. conclude 
that there is tremendous therapeutic potential in under-
standing and targeting epigenetic modification pathways 
[47]. In particular, investigating the cooperation of chro-
matin remodelers and the transcriptional machinery is 
not only crucial for elucidating fundamental mechanisms 
of chromatin regulation but also necessary for the design 
of targeted therapeutics.
It was also shown that integrating differentially meth-
ylated genes, which have been identified with ML-based 
approaches, and gene expression data in a network con-
text permits greater resolution for cancer-associated 
genes and pathways than observed previously [48]. Inte-
grational studies with proteomics and epigenetics data 
can extend common protein–protein interaction net-
works, which are exclusively focused on protein–protein 
associations and resulting in cell activities. In particular, 
Zaghlool et  al. [49] were able to link DNA methylation 
to disease endpoints via intermediate proteomics phe-
notypes and identify correlative networks that may even-
tually be targeted in a personalized approach of chronic 
low-grade inflammation.
Similar to analyses with transcriptomics data, func-
tional enrichment analyses in epigenetics data can be 
performed by popular approaches, such as EnrichR [50], 
gProfiler [51], or by using the gometh function from the 
R missMethyl package [52], to investigate the biological 
impact of the discovered differentially expressed genes 
or methylated sites. Correlation studies with clinical out-
come data and patient subgrouping can be performed via 
clustering approaches, e.g., principal component analysis 
(PCA), or its co-embedded visualizations of t-distributed 
stochastic neighbor embedding (t-SNE), or uniform man-
ifold approximation and projection (UMAP) analyses.
Since more heterogeneous high-throughput data are 
constantly generated, further integration of genomics, 
transcriptomics, epigenetics, as well as further omics 
data into a single framework is needed for an improved 
data interpretation. One possibility for such an overarch-
ing integration of complex data is the currently released 
disease map for acute inflammation resolution that may 
also serve as a prime example to facilitate the overall 
characterization of key-regulator processes in CD on a 
cellular level [53]. In particular, a complex disease phe-
notype, such as CD and IBD, can be comprehensively 
investigated considering the hierarchal organization 
of interacting components by a disease map (Fig.  1). In 
general, such a disease map can serve as an overarch-
ing knowledgebase to collect multiple kinds of data in a 
structured manner. In addition to a static data collection, 
such a framework offers the possibility for computational 
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modeling to perform in silico experiments. For example, 
it would be possible to simulate knock-out gene experi-
ments and retrieve the potential effect of the disease 
phenotype. This can be achieved because a disease map 
consists of three interconnected layers, which combine 
molecular pathway information, biological processes, and 
phenotypic outcomes. The top phenotypic layer high-
lights interactions at the tissue and cellular level, where 
a large number of immune cell types and tissue remod-
eling derive the clinical outcome (Fig.  1a). The middle 
layer describes connections between cellular processes 
and phenotypes (e.g., recognition of pathogens, invasion 
of neutrophils, resolution of inflammation, and effero-
cytosis). This layer also provides an interplay between 
key molecules associated with the underlying processes 
and resulting phenotypes (Fig.  1b). The computational 
simulations will be utilized within this layer by using all 
available information from the bottom layer. The bottom 
molecular interaction map layer contains all involved 
molecules and their regulatory components along with 
nonlinear regulatory motifs (e.g., feedback loops) and 
interactions (e.g., activation and inhibition of connected 
neighbor genes) that may control the overall dynam-
ics of IBD (Fig. 1c). This information is usually gathered 
manually from domain experts to guarantee a well-
curated basis for all analyses. The actual omics data are 
integrated and visualized in this layer, which means that 
specific colors in the nodes can indicate different values, 
such as transcript expression or methylation ratio. Taken 
together, such novel overarching computational concepts 
likewise facilitate the integration of diverse omics data 
and establish a profound knowledge base for CD.
Epigenetic investigation in Crohn’s disease
Several DNA methylation studies investigating CD-
related epigenetic modifications are summarized in 
Tables 1 and 2.
Fig. 1 Hierarchal organization of an IBD disease map in three interconnected layers. a Representing the phenotypic layer to obtain an overview 
about the integrated content of the disease map. b Process description layer, c Molecular interaction map layer containing the relation of all 
involved genes for the complex disease investigation, in which the actual data can be integrated (colors can indicate different values, such as 
transcript expression, methylation ratio)
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DNA methylation studies on blood components 
from Crohn’s disease patients
Recent research has focused on the methylation land-
scape of the DNA from CD patients through epigenome-
wide association studies (EWAS). DNA methylation 
studies on blood samples from CD patients with inac-
tive or active disease are diverse and included analyses 
on whole blood samples [54], peripheral blood cells [55, 
56], peripheral leukocytes [57–59], including periph-
eral blood mononuclear cells (PBMCs) [60, 61], serum 
samples [62], or separated B cells [63], T cells [64], and 
monocytes [65] (Table 1). The majority of studies involve 
adult patients [54–56, 58, 60, 62, 63, 65], while a few arti-
cles describe the DNA methylation in pediatric donors 
[57, 59, 61, 64]. A comparison between these studies is 
difficult because DNA methylation is strongly affected 
by age, or environmental conditions, such as medication 
or nutrition [66]. Interestingly, the advantage of studies 
using pediatric patients is that they are mostly less influ-
enced by medication than adults suffering for a long time 
from IBD [67]. Thus, it is assumed that the epigenetic 
modifications more likely reflect the disease state. In 
addition to age, gender also influences methylation sta-
tus, which is why some studies include only subjects of 
the same sex [54, 58, 65]. This leads to better comparabil-
ity of results between patients and control subjects.
Cell-specific patterns in DNA methylation of CD 
patients were described in different subpopulations of 
blood cells [55, 63–65], enabling, for instance, the clus-
tering of monocytes by their methylation profile [55]. 
Therefore, the validity of epigenetic analyses in whole 
blood samples is limited since individual cell-specific sig-
nals may disappear against the background of other pre-
sent cells. For example, a study using CD patients found 
no different methylation profiles between CD patients 
and control subjects in whole blood samples. Still, in 
PBMCs from newly diagnosed pediatric CD patients 
the testis, prostate, and placenta-expressed protein 
(TEPP) gene showed CD-associated hypermethylation 
[59]. Interestingly, the effect was not detected in pedi-
atric CD patients receiving therapy, indicating that the 
methylation status is associated with the disease activity 
[59]. This was confirmed by results in PBMCs, where the 
DNA methylation-related gene expression of homeobox 
protein engrailed-1 (EN1), Wilms tumor protein (WT1), 
and fibroblast growth factor receptor 2 (FGFR2) was 
higher in PBMCs from patients with active CD, while PR 
domain containing 16 (PRDM16) and neurogenic locus 
notch homolog protein 4 (NOTCH4) expression was 
decreased compared with patients in remission [68]. The 
altered expression of genes associated with the identified 
methylation-regulated gene region was further evalu-
ated by gene expression analyses. Thereby, complement 
component 2 (C2), spondin-2 (SPON2), and lympho-
toxin beta receptor (LTBR) were found to be increased 
in patients with active CD but not in patients in remis-
sion. Interestingly, in this study, the tumor necrosis fac-
tor alpha (TNFA) gene expression was increased in both 
groups, indicating a general altered CD-associated gene 
expression, which is not related to the disease activity. 
Although the results of PBMCs indicate that the disease 
activity in CD is associated with an altered methylation 
pattern, the epigenetic regulation of different subpopula-
tions within PBMCs remains unclear.
Cell-specific studies identified hypermethylated and 
hypomethylated gene regions in monocytes of CD 
patients (RPS6KA2 and HCAC4, respectively) but no 
corresponding modifications in  CD4+ or  CD8+ T cell 
populations [55]. The hypermethylation of the ribosomal 
protein S6 kinase alpha-2 (RPS6KA2) gene is assumed to 
result in a reduced gene expression of the encoded pro-
tein kinase. In tumor cell lines, the reduced or absent 
expression of RPS6KA2 is associated with decreased 
apoptosis and increased proliferation [69], supporting 
earlier studies on the significance of RPS6KA2 for cellu-
lar growth, survival, and differentiation [70]. In contrast, 
HDAC4, responsible for the deacetylation of lysine resi-
dues on the N-terminal part of the core histones (H2A, 
H2B, H3, and H4), is hypomethylated in monocytes from 
CD patients [55], resulting in an increased expression of 
the gene. The deacetylation of lysine by deacetylases is 
an epigenetic mechanism of histone modification and is 
generally assumed to inhibit gene transcription. However, 
potential targets of assumed deacetylase-induced gene 
repression in CD patients have still to be investigated. 
The fact that epigenetic modifications were described 
in monocytes of CD patients but not in T cells supports 
previous findings that transcriptional altered monocytes 
play a central role in CD pathogenesis that might be 
investigated in more detail by using single-cell technolo-
gies [71]. Interestingly, the methylation profile of  CD14+ 
monocytes in female CD patients also differed at the level 
of the subpopulations (classical, intermediate, non-clas-
sical) [65], indicating different gene regulation according 
to the defined function of the respective subpopulation. 
However, on a genome-wide level, they did not identify 
statistically significant methylation differences when 
comparing CD patients vs. healthy subjects or CD 
patients with active disease vs. inactive disease patients 
[65], possibly due to the small number of subjects or high 
individual variances (Table 1).
Differences in the methylation status between blood-
derived immune cells were further investigated in a 
comprehensive study using a large cohort of 240 newly 
diagnosed IBD patients [55]. Interestingly, in T cells from 
CD patients, tyrosine-protein kinase TXK (TXK) was 
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identified as an immune-relevant target of cell-specific 
gene expression regulated by DNA methylation. Thereby, 
IBD-associated hypermethylation in the promoter region 
of TXK was negatively correlated with the gene expres-
sion in  CD8+ T cells but not in other cell types indicating 
relations to underlying genotype. Due to the critical role 
of the TXK gene for regulation of the adaptive immune 
response, function, and differentiation of conventional T 
cells or non-conventional natural killer T (NKT) cells, the 
authors postulate a translational potential for the use of 
DNA methylation as biomarkers, capable of predicting 
the outcome or course of disease [55]. However, in newly 
diagnosed pediatric CD patients, the DNA methylation 
pattern in  CD8+ T cells was only associated with age 
but not with the disease outcome [64]. A study on B cells 
from CD patients found 14 CD-specific CpG sites with 
altered methylation [63]. Several of the methylated loci 
found in CD are involved in immune system regulating 
pathways, like macrophage-stimulating protein receptor 
(MST1R), interleukin-16 (IL-16), interleukin-10 (IL-10), 
and leukemia inhibitory factor (LIF) [63].
Moreover, methylated loci found in IBD, such as B cell 
lymphoma 3 protein (BCL3), signal transducer, and acti-
vator of transcription 3 (STAT3), oncostatin-M (OSM), 
and signal transducer and activator of transcription 5 
(STAT5), are involved in regulation or downstream sign-
aling in the Interleukin-23 (IL-23) signaling pathway 
[72]. IL-23 is a heterodimeric cytokine with functions 
in innate and adaptive immunity that induces autoim-
mune inflammation and thus may be responsible for 
the pathogenesis of autoimmune inflammatory diseases, 
such as CD. Besides, several studies on blood samples 
from CD patients show DNA methylation alterations 
mostly in genes involved in immune-related pathways 
like immune system progresses, immune response, or 
defense response to bacteria [54–56, 58, 63, 65] (Fig. 2). 
However, due to the limited sample size and the minor 
effect sizes observed, many of the results have to be vali-
dated in larger cohorts to evaluate their potential as valu-
able biomarkers.
DNA methylation studies on tissue components 
from Crohn’s disease patients
Whole intestinal biopsies [67, 73, 74] or cells, isolated and 
cultured from intestinal biopsies [68, 75–79], were used 
to investigate potential CD-associated epigenetic modifi-
cations in gut tissue samples derived from pediatric [67, 
76, 79] or adult patients [68, 73–75, 77, 78]. An overview 
Fig. 2 Schematic collection of DNA methylation studies in CD patients investigated in different cell types. Left/blood: hypo- (↓) and 
hypermethylated (↑) genes in whole blood cells, peripheral blood cells (PBCs), peripheral blood leukocytes (PBLs), peripheral blood mononuclear 
cells (PBMCs), B cells, monocytes, and T cells; Right/Tissue: hypo- (↓) and hypermethylated (↑) genes in bowel biopsies, isolated intestinal epithelial 
cells (IECs), and isolated fibroblasts from biopsies of CD patients and human adipose stem cells (hASCs) isolated from subcutaneous adipose tissue 
of CD patients. Genes found in more than 1 study are marked in bold
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of the identified methylation-regulated genes, described 
in association with CD, is presented in Fig. 2. A study on 
intestinal epithelial cells (IECs) of human fetuses, healthy 
pediatric donors, and children newly diagnosed with CD 
displayed general differences between fetal and pediatric 
samples, indicating that DNA methylation is involved in 
the maturation and development of gut epithelium [79]. 
Furthermore, Kraiczy et  al. postulate that epigenetic 
changes during critical periods of fetal and postnatal 
development may predispose the onset of chronic intesti-
nal inflammation. In children newly diagnosed with CD, 
hypermethylated regions were identified in immune rele-
vant genes, such as mucin (MUC2) and polymeric immu-
noglobulin receptor (PIGR), indicating a suppressed gene 
transcription. Interestingly, clustering analysis of methyl-
ation profiles between IBD (including both CD and ulcer-
ative colitis (UC) patients) and healthy controls revealed 
that the subset of IBD appeared not to be entirely due 
to the presence of inflammation, which was assumed to 
reflect an IBD-specific intestinal epithelial DNA methyla-
tion signature in these patients [79].
When comparing inflamed and non-inflamed biopsies 
of adult CD patients, it is not surprising that specific IBD 
associated genes are altered in their methylation state, 
for example, unc-51 like autophagy activating kinase 1 
(ULK1), docking protein 2 (DOK2), and antigen peptide 
transporter 1 (TAP1) [74]. ULK1 is an essential protein in 
autophagy in response to starvation [72, 80] and hyper-
methylated in inflamed rectal biopsies from CD patients 
compared with controls, which means that the ULK1 
gene expression is decreased [74]. It is well described that 
autophagic dysfunctions play multiple roles in the patho-
genesis of IBD and, in particular, in CD [81, 82]. Also, 
several genetic variants are linked to CD, such as nucleo-
tide-binding oligomerization domain-containing protein 
2 (NOD2) or autophagy-related protein 16–1 (ATG16L1) 
[81]. In contrast to ULK1, DOK2 and TAP1 are hypo-
methylated in CD patients, which leads to an increased 
gene expression. Both genes are involved in inflamma-
tion-related immune response, such as cytokine- or anti-
gen-induced signaling, respectively [72]. The association 
between inflammation and methylation state was further 
confirmed in studies investigating epigenetic modifica-
tion by medication. Thereby, differences in DNA methyl-
ation between previously inflamed tissue of CD patients 
and healthy subjects were gone after medicinal treatment 
[74], indicating a direct effect of acute inflammatory 
mediators on epigenetic modulation.
Researchers investigated 236 IEC samples from dif-
ferently localized mucosal biopsies of the intestine from 
pediatric patients with IBD or healthy controls to evalu-
ate the role of methylation independently of the inflam-
matory status [76]. In this context, segment-specific DNA 
methylation differences were described in the region of 
terminal ileum between CD patients and healthy con-
trols, indicating CD-associated epigenetic patterns. 
Interestingly, these changes appear to be specific to CD, 
as no differences were found in UC. In contrast, the 
authors described the epigenetic changes observed in 
the colon as common IBD signature because the differ-
ences in DNA methylation occurred in CD patients and 
in patients with UC. This suggestion is supported by 
the investigation of the DNA methylation landscape in 
colon biopsies from pediatric UC and CD patients. They 
showed similar DNA methylation alterations in 50% of 
the verified genes between CD and UC patients [67].
A serious complication of CD is fibrosis-associated 
strictures, which may cause intestinal obstruction. Epi-
genetic studies have shown that alterations in the DNA 
methylation landscape are associated with fibrosis-
associated complications in CD patients [75, 78]. When 
comparing biopsy samples of non-inflamed (NINF) tis-
sues, inflamed tissues (INF), and stenotic tissues (STEN) 
from CD patient biopsies with control subject samples, 
in one study, 44 different methylated positions (DMPs), 
38 different methylated regions (DMRs), and 11 different 
expressed genes (DEGs) were found [78]. However, most 
methylation differences occurred when comparing CD-
INF with CD-NINF or CD-STEN with CD-NINF [78]. A 
further study detected 1,180 DMRs as hypermethylated 
and 802 DMRs as hypomethylated in the fibrotic sam-
ples compared to unaffected samples [75]. Furthermore, 
the authors found that the majority of differential DNA 
methylation was within introns (48.6% hypermethylated, 
43.1% hypomethylated) and intergenic regions (40.8% 
hypermethylated, 48.4% hypomethylated), which are 
involved in the regulation of gene transcription in addi-
tion to gene-associated promoters. For instance, DNA 
methylation in introns can modulate alternative exon 
splicing, while intergenic sequences contain enhanc-
ers and insulators associated with the regulation of gene 
expression [83, 84]. In gene promoter regions, only 5% of 
the DMRs were hypermethylated and 2.7% hypomethyl-
ated [75]. Both studies on fibrosis-associated complica-
tions observed downregulation of the WNT signaling 
pathway member WNT2B, which was correlated with 
increased DNA methylation [75, 78]. During intesti-
nal inflammation, WNT2B and other canonical WNT 
ligands, such as WNT1, WNT3A, and WNT10A, are pro-
duced by intestinal macrophages [85–87], mucosal den-
dritic cells [88], and T cells [89] and secreted to activate 
WNT/β-catenin signaling in crypt base columnar (CBC) 
stem cells, thereby promoting epithelial regeneration 
after tissue damage [90]. Accordingly, it can be assumed 
that an interruption of the signal harms mucosal heal-
ing and may contribute to chronic inflammation [90]. In 
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addition to WNT-signaling, multiple components of the 
E2 factor family of transcription factors (E2F) and fibro-
blast growth factor (FGF) pathway were observed to be 
downregulated by increased DNA methylation in biop-
sies samples from CD patients. Since E2F, WNT, and FGF 
signaling pathways are essential for cellular differentia-
tion, proliferation, and migration, it can be hypothesized 
that their abnormal behavior underlies tissue remodeling 
processes, resulting in the observed fibrostenotic pheno-
type [78].
In addition to intestine-derived samples, one recent 
study examined the DNA methylation status of human 
adipose stem cells (hASCs) from CD patients [68] as 
they showed dysfunction in proliferation, lipid enrich-
ment, and immunomodulation in quiescent CD [77]. 
Several different methylated and expressed genes (Fig. 2) 
were involved in immune system responses, metabo-
lism, cell differentiation, and development processes 
[68]. Interestingly, they also compared the methylation 
and gene expression results from hASCs with PBMCs 
from patients with active and inactive CD and found that 
genes, which are differentially methylated in both cell 
subsets, were related to the immune system and cell dif-
ferentiation processes. Furthermore, the study showed 
that changes in DNA methylation-related gene expres-
sion in hASCs are only partially restored in quiescent 
CD, which was similar to the effects observed in PBMCs 
[68]. This suggests that epigenetic modifications may 
induce the persistence of latent inflammation against a 
background of apparent clinical remission.
Histone modification studies in Crohn’s disease patients
In contrast to global methylation patterns, histone modi-
fications have been less extensively studied in CD than 
DNA methylation. A recent study found that the histone 
methylation profile at H3K4 changes when the microbi-
ome altered resulting from the disease [91]. The epige-
netic changes are related to genes involved in regulating 
cytokine signaling, metabolism, homeostasis, and reac-
tive oxygen species [91]. A significant proportion of the 
analyzed genes had trimethylation of H3K4 (H3K4me3), 
one of the least abundant histone modifications and posi-
tively correlates with transcription [92]. In CD patients, 
levels of H3K4me3 correlated with the severity of bowel 
inflammation, although significant differential expres-
sion was lacking [91]. Moreover, Turgeon et  al. showed 
that H3K27 marks might control both cell proliferation 
and inflammatory response by regulating specific signal-
ing pathways, either negatively for the STAT3 pathway or 
positively for the p38 mitogen-activated protein kinase 
(MAPK) pathway [93]. Even the slightest modifications 
in polycomb repressive complex 2 (PRC2) activity lead 
to variations in H3K27 methylation and to activation 
or repression of parallel pathways of gene activity. In 
the context of genetic disorders, this results in both 
increased proliferation and intrinsic inflammatory gene 
stimulation. Furthermore, in two animal models for 
intestinal inflammation and intestinal biopsies of patients 
with CD, it was shown that the acetylation of histone H4 
in the inflamed mucosa was significantly increased in the 
trinitrobenzene sulfonic acid model of colitis, especially 
on lysine residues 8 and 12 in contrast to non-inflamed 
tissue [94], indicating an activation of the related gene 
region. Besides, acetylated H4 was localized on inflamed 
tissue and Peyer’s patch during dextran sulfate sodium 
(DSS)-induced colitis in rats, and H4 acetylation was also 
significantly upregulated in inflamed biopsies and on the 
Peyer’s patch in patients with CD. Another study found 
56 potential target genes for H3K27ac change in colon 
tissue from mice upon DSS treatment [95]. It can there-
fore be assumed that histone acetylation is associated 
with intestinal inflammation in CD patients and may rep-
resent a new therapeutic target for mucosal healing [94].
Epigenetic signatures as biomarkers in CD
Changes in the DNA methylation status of CD-associ-
ated genes significantly alter transcriptional activity and 
expression levels of genes, thereby influencing disease 
risk and progression. Interestingly, some DNA meth-
ylation profiles apply to both CD and UC, while others 
are specific to CD or UC, creating new and meaning-
ful rationales for disease classification and therapy [74]. 
Also, epigenetic analysis has found several differentially 
methylated genes involved in IBD that were not previ-
ously identified as IBD risk genes in GWAS.
The diagnosis of IBD is primarily based on clinical 
imaging, as well as endoscopic and histological findings. 
Furthermore, the emergence of genetic, serological, and 
fecal markers in the diagnosis and classification of the 
disease is also growing. Especially in the differentiation 
between UC and CD, biomarkers can be of high rele-
vance for an early, correct diagnosis and optimal therapy. 
Despite all these possibilities, some patients are still diag-
nosed with “IBD-unclassified” or “indeterminate colitis” 
because a clear assignment to CD or UC is not possible. 
Molecular markers, such as DNA methylation and his-
tone modifications, could have certain advantages in 
terms of sensitivity, specificity, and accuracy when used 
in conjunction with other surrogates, such as NOD2, 
anti-Saccharomyces cerevisiae antibodies (ASCA), anti-
neutrophil cytoplasmic antibodies (ANCA), fecal cal-
protectin (FC), and fecal lactoferrin (FL) [96, 97]. At 
the epigenetic level, microRNAs in particular currently 
assume a central role in biomarker development in CD, 
compared with DNA methylation and histone modifica-
tions [98].
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As shown in Fig.  2, a subset of genes are found to be 
differentially methylated in independent studies, for 
example, TNF, Tumor Necrosis Factor Ligand Super-
family Member 4 (TNFSF4), IL-19, IL-10, RPS6KA2, 
and Spi-1 proto-oncogene (SPI1) (Fig.  2). Hypometh-
ylation of TNF and consequent increased gene expres-
sion, and hypermethylation of TNFSF4 and consequent 
repressed gene expression, were found in both blood 
and tissue samples, whereas hypermethylation of IL-10 
and RPS6KA2, as well as hypomethylation of SPI1, could 
only be detected in blood samples from CD patients. 
TNF, as a pro-inflammatory cytokine, plays an essential 
role in local and systemic inflammation, so that activa-
tion of gene expression in CD is not surprising. Increased 
TNF secretion was found deeper in the lamina propria 
and submucosa of CD patients [99–101]. Furthermore, 
TNF levels were elevated in stool samples from patients 
with active CD compared with inactive CD patients and 
healthy controls, although serum concentrations were 
less pronounced [101–104]. However, due to the multi-
functional mode of action of TNF, methylation change is 
not suitable as a biomarker for the identification of CD 
but only shows whether inflammation is present or not.
Different DNA methylation of SPI1 and RPS6KA2 has 
been demonstrated in both whole blood and isolated 
monocytes. SPI1 is responsible for developing myeloid 
and B-lymphoid cells [105], whereas RPS6KA2 regu-
lates different cellular processes, including cell growth, 
cell motility, proliferation, and cell cycle progression 
[55, 106]. Presumably, the altered DNA methylations 
are cell-specific aspects that tend to be involved in the 
development and differentiation of monocytes them-
selves rather than CD’s pathogenesis. Future studies 
would have to take into account that different cell types 
may have diverse DNA methylation landscapes, which 
is crucial to decipher and elucidate the exact functional 
consequences of epigenetic changes in IBD pathogenesis. 
Another limitation points to results obtained in studies 
with small sample sizes that have to be verified in large, 
well-designed, prospective studies.
Conclusions
Our knowledge of the functional significance of epi-
genetic modifications in CD is still limited, although 
EWAS have contributed to a better understanding of 
the pathogenesis of IBD. Most of the described studies 
examined DNA methylation changes between patients 
and control subjects to find biomarkers for an early IBD 
identification, or more specifically, to enable a differen-
tial diagnosis between CD and UC. However, specific 
patterns of DNA methylation and histone modifica-
tions might be used as alternative biomarkers of disease 
activity or progression and novel targets for therapeutic 
interventions in IBD patients. Thus, it will be neces-
sary to decipher and elucidate the precise functional 
consequences of genetic and epigenetic alterations in 
CD’s pathogenesis to pave the way for the development 
of novel therapeutic strategies. The fact that different 
cell types have diverse DNA methylation landscapes 
has to be considered. Moreover, it should be taken into 
account that the epigenetic changes may be reversible, 
for example, by drugs, and are caused not only by the 
disease status but also by environmental factors, which, 
however, influence the pathogenesis of the disease. The 
questions at that point are: [1] Is the epigenetic modifi-
cation altered due to the disease or is the disease driven 
due to the epigenetic modification, and (2) how do epi-
genetic modifications contribute to the pathogenesis of 
CD? Are there CD-specific signatures, which provide 
additional value as disease-related biomarkers or serve 
as targets for therapeutic interventions? Epigenetic 
methods opened up a broad field of research to answer 
these questions and improve our knowledge of the 
immune dysregulation that leads to CD. Computational 
models based on experimentally identified biomarkers 
may help clinicians for an improved disease characteri-
zation and/or predict the disease’s course. Since epi-
genetic modifications are dynamic and reversible, they 
could ultimately serve as novel essential therapeutic 
targets.
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